BIOPHYSICAL THERAPEUTICS, INC.
Raising nowOperatingBiophysical Therapeutics, Inc.
Biotech · Biotech · Wilmington, DE · Founded 2022
Trying to develop a drug to slow aging
This company has an open fundraising round.
Financials
FY2021–FY2025 (no data for FY2023) · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Fundraising history
Team
3 people
Professor Emeritus at The Scripps Research Institute. Where he led a team that extended lifespan in mice, which was published in the prestigious scientific journal Science.
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 3 annual reports (FY2023–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGAR- Form CJul 7, 20260001980213-26-000004EDGAR
- Form C-TRMay 19, 20260001980213-26-000003EDGAR
- Form C-ARMay 18, 20260001980213-26-000002EDGAR
- Form C-UOct 21, 20240001670254-24-001009EDGAR
- Form C-UOct 21, 20240001670254-24-001010EDGAR
- Form C/ADec 20, 20230001670254-23-001170EDGAR
- Form COct 17, 20230001670254-23-000971EDGAR
- Form DAug 21, 20230001980213-23-000003EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.